Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension-Reference-Cited by-同舟云学术

Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension

Published:2012-06-15 Issue:6 Volume:7 Page:e38364
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Schuster Cornelia,Eikesdal Hans P.,Puntervoll Hanne,Geisler Jürgen,Geisler Stephanie,Heinrich Daniel,Molven Anders,Lønning Per E.,Akslen Lars A.,Straume Oddbjørn

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.;MR Middleton;J Clin Oncol,2000

2. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.;MB Atkins;J Clin Oncol,1999

3. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.;C Busch;Eur J Cancer,2010

4. Improved survival with ipilimumab in patients with metastatic melanoma.;FS Hodi;N Engl J Med,2010

5. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.;PB Chapman;N Engl J Med,2011

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pericytes: jack-of-all-trades in cancer-related inflammation;Frontiers in Pharmacology;2024-07-17

2. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives;Life Sciences;2024-05

3. Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors;Internal Medicine;2024

4. β2‐adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma;Cancer Medicine;2023-08-08

5. Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies;Frontiers in Pharmacology;2023-07-13